Vivaldi Biosciences

About Vivaldi Biosciences

Vivaldi Biosciences is a biotechnology company focused on developing innovative vaccines for viral respiratory diseases. The company operates primarily in the healthcare and pharmaceutical markets, targeting both epidemic and pandemic threats. Vivaldi's flagship product is DeltaFLU, a universal influenza vaccine designed to protect against all strains of influenza, whether seasonal or pandemic. This vaccine is unique because it is administered as a nasal spray and is self-adjuvanting, meaning it enhances its own effectiveness without needing additional substances.

The company serves a broad range of clients, including healthcare providers, government health agencies, and potentially, global health organizations. Vivaldi's DeltaFLU vaccine is currently in Phase 2 clinical development, which means it is being tested for safety and effectiveness in a larger group of people. The European Union is funding part of this clinical development through a consortium called FLUniversal, which includes Vivaldi and other academic and industry partners.

Vivaldi's business model revolves around research and development (R&D) of its Delta NS1 technology platform, which underpins its vaccine products. The company aims to generate revenue through the successful commercialization of its vaccines, which would involve selling them to healthcare providers and governments. Additionally, Vivaldi may seek partnerships or licensing agreements with larger pharmaceutical companies to expand its market reach.

In summary, Vivaldi Biosciences is at the forefront of developing next-generation vaccines for viral respiratory diseases, with a particular focus on influenza. The company's innovative approach and strategic partnerships position it well in the competitive biotech landscape.